Ixamail Fraire-Soto, Jorge Gustavo Araujo-Huitrado, Angelica Judith Granados-López, Luis A. Segura-Quezada, Rafael Ortiz-Alvarado, Mayra Denise Herrera, Rosalinda Gutiérrez-Hernández, Claudia Araceli Reyes-Hernández, Yamilé López-Hernández, Melissa Tapia-Juárez, José Vicente Negrete-Díaz, Luis Chacón-García, César R. Solorio-Alvarado and Jesús Adrián López* Pages 1 - 12 ( 12 )
Background: A family of 4H-benzo[d][1,3]oxazines were obtained from a group of N-(2-alkynyl)aryl benzamides precursors via gold(I) catalysed chemoselective 6-exo-dig C-O cyclization.
Method: The precursors and oxazines obtained were studied in breast cancer cell lines MCF-7, CAMA-1, HCC1954 and SKBR-3 with differential biological activity showing various degrees of inhibition with a notable effect for those that had an aryl substituted at C-2 of the molecules. 4H-benzo[d][1,3]oxazines showed an IC50 rating from 0.30 to 157.4 µM in MCF-7, 0.16 to 139 in CAMA-1, 0.09 to 93.08 in SKBR-3, and 0.51 to 157.2 in HCC1954 cells.
Results: We observed that etoposide is similar to benzoxazines while taxol effect is more potent. Four cell lines responded to benzoxazines while SKBR-3 cell line responded to precursors and benzoxazines. Compounds 16, 24, 25 and 26 have the potent effect in cell proliferation inhibition in the 4 cell lines tested and correlated with oxidant activity suggesting a possible mechanism by ROS generation.
Conclusion: These compounds represent possible drug candidates for the treatment of breast cancer. However, further trials are needed to elucidate its full effect on cellular and molecular features of cancer.
Breast Cancer,Cell Lines,Benzoxazines,Proliferation,Oxidation,Reduction.